

October 20, 2006
Shionogi & Co., Ltd.

**Shionogi Obtained Manufacturing and Marketing Approval for Cancer Pain
Analgesic OXINORM powder 0.5% (Oxycodone Hydrochloride Hydrate)**

Osaka, October 20, 2006 — Shionogi & Co., Ltd. (Head Office: Osaka; President: Motozo Shiono) received manufacturing and marketing approval on October 20 for OXINORM powder 0.5% (oxycodone hydrochloride hydrate), a powder analgesic for cancer pain. Shionogi plans to launch this product in February 2007, after National Health Insurance (NHI) price listing.

Licensed from Netherlands-based Mundipharma B.V., OXINORM powder 0.5% has the same composition as OxyContin[®] Tablets, which Shionogi launched in July 2003. Shionogi has developed it as an immediate-release powder analgesic for combined use with OxyContin[®] Tablets in treating cancer pain, when dosage adjustment is needed or sudden pain (breakthrough pain) occurs.

Combined use of sustained-release and immediate-release analgesics with the same composition and administration route is the method of cancer pain treatment recommended by the World Health Organization (WHO). The approval of OXINORM powder 0.5% will enable more effective management of cancer pain in combination with OxyContin[®] Tablets.

Shionogi will work to provide information on proper use of OxyContin[®] Tablets and OXINORM powder 0.5%, so that cancer patients can lead peaceful lives free from pain.

For further information, contact:

Public Relations Unit
Shionogi & Co., Ltd.
(Osaka)

Tel: +81-6-6209-7885 Fax: +81-6 6229-9596

(Tokyo)

Tel: +81-3-3406-8164 Fax: +81-3-3406-8099

#